Clinical TrialAug 12, 2026, 04:07 PM
Atea Pharma's BEM/RZR Phase 3 C-BEYOND met endpoints for HCV
AI Summary
Atea Pharmaceuticals announced positive topline results from its Phase 3 C-BEYOND trial, where its BEM/RZR regimen met primary and secondary endpoints for treating chronic Hepatitis C Virus (HCV), demonstrating potential as a best-in-class treatment. The company also reported that its C-FORWARD Phase 3 trial is on track for early Q1 2027 results and initiated a Phase 1 trial for AT-587 for Hepatitis E Virus (HEV). For Q2 2026, Atea reported $219.5 million in cash and investments and a net loss of $32.9 million.
Key Highlights
- Phase 3 C-BEYOND trial met primary and secondary endpoints for HCV treatment.
- BEM/RZR achieved 93.9% SVR rate vs. 94.8% for SOF/VEL in mITT population.
- Non-cirrhotic patients (8-week BEM/RZR) showed 93.5% SVR rate vs. 94.6% for SOF/VEL (12-week).
- C-FORWARD Phase 3 trial topline results expected early Q1 2027.
- AT-587 Phase 1 clinical trial advancing for Hepatitis E Virus (HEV).
- Cash and investments were $219.5 million at June 30, 2026.
- Q2 2026 R&D expenses decreased to $28.2 million from $32.3 million YoY.
- Q2 2026 net loss was $32.9 million compared to $37.2 million YoY.
Price Impact
More from AVIR